ARQT
Arcutis Biotherapeutics, Inc.
$24.38
-0.85%
$3.0B
No data for this timeframe.
Vol
Market Cap$3.0B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (86%)
Inst. Holders50 funds
Inst. Value$1.7B
Inst. Activity17 buys / 10 sells
Insider Activity0B / 21S
Insider Net $-$3.8M
SEC Reports8
Congressional1 trades
Recent Activity
Jun 29, 2026
fda_pdufa
PDUFA: ARQT — ZORYVE in plaque psoriasis down to 2 years of age — 2026-06-29
FDA target action date 2026-06-29 for ARQT (Arcutis Biotherapeutics, Inc.). Drug: ZORYVE. Indication
Jun 9, 2026
SEC
Arcutis Biotherapeutics filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders, where all three p
8-K — Impact 2/10
Jun 5, 2026
Insider
Heron Patrick J was granted 16,667 shares
Director
Jun 5, 2026
Insider
Krishnamohan Neha was granted 16,667 shares
Director
Jun 5, 2026
Insider
Krishnamohan Neha was granted 5,778 shares
Director
May 13, 2026
SEC
Four Arcutis insiders sold a total of $283K in open-market sales over a one-week window, including the CFO and three oth
CLUSTER — Impact 3/10
May 11, 2026
SEC
Director Patrick Burnett filed a Form 144 notice of intent to sell 222 shares of Arcutis Biotherapeutics (ARQT) worth ap
144 — Impact 1/10
Inst.
JENNISON ASSOCIATES LLC — TRIM
4,980,770 shares ($117.3M)
Price Targets
$34.63
+42.0% upside
Strong Buy
Current $24.38
Low $33.00
Median $35.00
High $36.00
8 analysts
$33.00
$36.00
Analyst Ratings
4Strong Buy
8Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 7, 2026 | Needham | REITERATE | Buy → Buy |
| Mar 2, 2026 | Mizuho | MAINTAIN | Outperform → Outperform |
| Feb 27, 2026 | Guggenheim | MAINTAIN | Buy → Buy |
| Feb 26, 2026 | TD Cowen | MAINTAIN | Buy → Buy |
| Feb 26, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.05 ▼ -28.2% | $0.02 — $0.08 | 136% YoY | 3 |
| Next Q | $0.09 ▼ -35.8% | $0.06 — $0.16 | 53% YoY | 5 |
| Current FY | $0.24 ▼ -33.3% | $0.18 — $0.33 | 288% YoY | 4 |
| Next FY | $1.16 ▼ -9.6% | $0.79 — $1.61 | 372% YoY | 7 |
Latest Reports
NEUTRAL
8-K
2/10
Arcutis Biotherapeutics filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders, where all three p
Jun 9, 2026
NEUTRAL
CLUSTER
3/10
Four Arcutis insiders sold a total of $283K in open-market sales over a one-week window, including the CFO and three oth
May 13, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $216.8M | — |
| Rubric Capital Management LP | $194.9M | — |
| STATE STREET CORP | $148.3M | — |
| Polar Capital Holdings Plc | $133.5M | — |
| JENNISON ASSOCIATES LLC | $117.3M | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 5, 2026 | Heron Patrick | A | $0.00 |
| Jun 5, 2026 | Krishnamohan Neha | A | $0.00 |
| Jun 5, 2026 | Krishnamohan Neha | A | $0.00 |
| Jun 5, 2026 | Munshi Amit | A | $0.00 |
| Jun 5, 2026 | Munshi Amit | A | $0.00 |
Congressional Trades
1 members: 1 buys, 0 sells
| Member | Party | Type | Amount |
|---|---|---|---|
| Gilbert Cisneros | D | BUY | $1,001 - $15,000 |
50 institutional holders with $1.7B total value (73,742,887 shares) as of 2026-Q1. Top holders: BlackRock,, Rubric, STATE. Net buying activity: 17 institutions added/increased vs 10 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 9,200,411 | $216.8M | 12.5% | — |
| 2 | Rubric Capital Management LP | 8,271,577 | $194.9M | 11.2% | — |
| 3 | STATE STREET CORP | 6,296,197 | $148.3M | 8.5% | — |
| 4 | Polar Capital Holdings Plc | 5,666,940 | $133.5M | 7.7% | — |
| 5 | JENNISON ASSOCIATES LLC | 4,980,770 | $117.3M | 6.8% | TRIM -26.3% |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 4,871,536 | $114.8M | 6.6% | — |
| 7 | MORGAN STANLEY | 4,218,931 | $99.4M | 5.7% | — |
| 8 | D. E. Shaw & Co., Inc. | 2,496,222 | $58.8M | 3.4% | ADD +26.6% |
| 9 | MARSHALL WACE, LLP | 2,431,778 | $57.3M | 3.3% | DOUBLED +435.4% |
| 10 | FRANKLIN RESOURCES INC | 2,297,943 | $54.1M | 3.1% | — |
| 11 | DRIEHAUS CAPITAL MANAGEMENT LLC | 2,226,029 | $52.4M | 3.0% | DOUBLED +133.6% |
| 12 | BANK OF AMERICA CORP /DE/ | 2,221,289 | $52.3M | 3.0% | ADD +32.7% |
| 13 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1,954,685 | $46.1M | 2.7% | — |
| 14 | JANUS HENDERSON GROUP PLC | 1,854,566 | $43.7M | 2.5% | — |
| 15 | GOLDMAN SACHS GROUP INC | 1,603,013 | $37.8M | 2.2% | — |
| 16 | FEDERATED HERMES, INC. | 1,077,267 | $25.4M | 1.5% | — |
| 17 | BAMCO INC /NY/ | 1,072,189 | $25.3M | 1.5% | DOUBLED +112.4% |
| 18 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,012,555 | $23.9M | 1.4% | — |
| 19 | Nuveen, LLC | 902,134 | $21.3M | 1.2% | TRIM -34.7% |
| 20 | VANGUARD FIDUCIARY TRUST CO | 771,764 | $18.2M | 1.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| JENNISON ASSOCIATES LLC | TRIM | 6,758,006 | 4,980,770 | -26.3% | $117.3M | 2026-Q1 |
| MARSHALL WACE, LLP | DOUBLED | 454,233 | 2,431,778 | +435.4% | $57.3M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | ADD | 1,673,454 | 2,221,289 | +32.7% | $52.3M | 2026-Q1 |
| BAMCO INC /NY/ | DOUBLED | 504,700 | 1,072,189 | +112.4% | $25.3M | 2026-Q1 |
| Nuveen, LLC | TRIM | 1,382,160 | 902,134 | -34.7% | $21.3M | 2026-Q1 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | TRIM | 900,000 | 636,200 | -29.3% | $15.0M | 2026-Q1 |
| Point72 Asset Management, L.P. | ADD | 425,152 | 590,877 | +39.0% | $13.9M | 2026-Q1 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | TRIM | 914,020 | 540,511 | -40.9% | $12.7M | 2026-Q1 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | DOUBLED | 125,979 | 503,856 | +300.0% | $11.9M | 2026-Q1 |
| M&G Plc | NEW | — | 469,082 | — | $11.3M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 273,999 | 440,999 | +60.9% | $10.4M | 2026-Q1 |
| DEUTSCHE BANK AG\ | TRIM | 930,202 | 389,847 | -58.1% | $9.2M | 2026-Q1 |
| FMR LLC | ADD | 205,424 | 278,736 | +35.7% | $6.6M | 2026-Q1 |
| JUPITER ASSET MANAGEMENT LTD | TRIM | 326,538 | 217,255 | -33.5% | $5.1M | 2026-Q1 |
| SEI INVESTMENTS CO | ADD | 104,286 | 206,141 | +97.7% | $4.9M | 2026-Q1 |
| LAZARD ASSET MANAGEMENT LLC | ADD | 93,354 | 154,566 | +65.6% | $3.6M | 2026-Q1 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | DOUBLED | 64,503 | 154,422 | +139.4% | $3.6M | 2026-Q1 |
| Invesco Ltd. | TRIM | 307,382 | 139,843 | -54.5% | $3.3M | 2026-Q1 |
| Pictet Asset Management Holding SA | ADD | 87,687 | 138,112 | +57.5% | $3.0M | 2026-Q1 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | ADD | 57,136 | 104,356 | +82.6% | $2.2M | 2026-Q1 |
| MACKENZIE FINANCIAL CORP | ADD | 49,025 | 88,261 | +80.0% | $2.1M | 2026-Q1 |
| Rockefeller Capital Management L.P. | NEAR_EXIT | 551,958 | 19,597 | -96.4% | $461.7K | 2026-Q1 |
| VOYA INVESTMENT MANAGEMENT LLC | TRIM | 39,884 | 18,890 | -52.6% | $445.0K | 2026-Q1 |
| Merit Financial Group, LLC | ADD | 13,017 | 18,852 | +44.8% | $444.2K | 2026-Q1 |
| PNC FINANCIAL SERVICES GROUP, INC. | ADD | 13,597 | 17,597 | +29.4% | $414.6K | 2026-Q1 |
13 unique insiders with 49 transactions. Net insider value: -$3.8M ($0.00 bought, $3.8M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 5, 2026 | Heron Patrick J | Director | AWARD | 16,667 | — | — |
| Jun 5, 2026 | Krishnamohan Neha | Director | AWARD | 16,667 | — | — |
| Jun 5, 2026 | Krishnamohan Neha | Director | AWARD | 5,778 | — | — |
| Jun 5, 2026 | Munshi Amit | Director | AWARD | 16,667 | — | — |
| Jun 5, 2026 | Munshi Amit | Director | AWARD | 5,778 | — | — |
| Jun 5, 2026 | Gilbert Halley E | Director | AWARD | 16,667 | — | — |
| Jun 5, 2026 | Gilbert Halley E | Director | AWARD | 5,778 | — | — |
| Jun 5, 2026 | Heron Patrick J | Director | AWARD | 5,778 | — | — |
| Jun 5, 2026 | Welgus Howard G. | Director | AWARD | 16,667 | — | — |
| Jun 5, 2026 | Welgus Howard G. | Director | AWARD | 5,778 | — | — |
| Jun 5, 2026 | LIN SUE-JEAN | Director | AWARD | 16,667 | — | — |
| Jun 5, 2026 | LIN SUE-JEAN | Director | AWARD | 5,778 | — | — |
| Jun 5, 2026 | Leonard Keith R | Director | AWARD | 16,667 | — | — |
| Jun 5, 2026 | Leonard Keith R | Director | AWARD | 5,778 | — | — |
| Jun 5, 2026 | Curran Terrie | Director | AWARD | 16,667 | — | — |
| Jun 5, 2026 | Curran Terrie | Director | AWARD | 5,778 | — | — |
| May 11, 2026 | Burnett Patrick | See Remarks | SELL | 222 | $21.05 | $4.7K |
| May 11, 2026 | Vairavan Latha | SVP Chief Financial Officer | SELL | 435 | $21.05 | $9.2K |
| May 4, 2026 | Watanabe Todd | See Remarks | SELL | 3,172 | $23.61 | $74.9K |
| May 4, 2026 | Vairavan Latha | SVP Chief Financial Officer | SELL | 1,341 | $23.61 | $31.7K |
| May 4, 2026 | Burnett Patrick | See Remarks | SELL | 684 | $23.61 | $16.1K |
| May 4, 2026 | Matsuda Masaru | See Remarks | SELL | 7,372 | $23.27 | $171.5K |
| May 1, 2026 | Welgus Howard G. | Director | SELL | 7,144 | $22.99 | $164.2K |
| Apr 1, 2026 | Welgus Howard G. | Director | SELL | 10,000 | $23.88 | $238.8K |
| Mar 2, 2026 | Edwards Larry Todd | See Remarks | SELL | 3,584 | $25.16 | $90.2K |
| Mar 2, 2026 | Watanabe Todd | See Remarks | SELL | 36,281 | $25.16 | $912.9K |
| Mar 2, 2026 | Matsuda Masaru | See Remarks | SELL | 6,553 | $25.16 | $164.9K |
| Mar 2, 2026 | Burnett Patrick | See Remarks | SELL | 6,106 | $25.16 | $153.6K |
| Mar 2, 2026 | Vairavan Latha | SVP Chief Financial Officer | SELL | 2,772 | $25.16 | $69.7K |
| Mar 2, 2026 | Leonard Keith R | Director | EXERCISE | 27,052 | $8.63 | $233.5K |
| Mar 2, 2026 | Welgus Howard G. | Director | SELL | 10,000 | $25.65 | $256.5K |
| Feb 27, 2026 | Edwards Larry Todd | See Remarks | AWARD | 77,000 | — | — |
| Feb 27, 2026 | Watanabe Todd | See Remarks | AWARD | 102,000 | — | — |
| Feb 27, 2026 | Watanabe Todd | See Remarks | AWARD | 266,000 | — | — |
| Feb 27, 2026 | Matsuda Masaru | See Remarks | AWARD | 37,000 | — | — |
| Feb 27, 2026 | Matsuda Masaru | See Remarks | AWARD | 97,000 | — | — |
| Feb 27, 2026 | Burnett Patrick | See Remarks | AWARD | 77,000 | — | — |
| Feb 27, 2026 | Edwards Larry Todd | See Remarks | AWARD | 30,000 | — | — |
| Feb 27, 2026 | Vairavan Latha | SVP Chief Financial Officer | AWARD | 27,000 | — | — |
| Feb 27, 2026 | Vairavan Latha | SVP Chief Financial Officer | AWARD | 70,000 | — | — |
| Feb 27, 2026 | Burnett Patrick | See Remarks | AWARD | 30,000 | — | — |
| Feb 4, 2026 | Burnett Patrick | See Remarks | SELL | 9,794 | $25.81 | $252.7K |
| Feb 2, 2026 | Burnett Patrick | See Remarks | SELL | 3,675 | $25.50 | $93.7K |
| Feb 2, 2026 | Matsuda Masaru | See Remarks | SELL | 7,983 | $25.50 | $203.6K |
| Feb 2, 2026 | Watanabe Todd | See Remarks | SELL | 19,833 | $25.50 | $505.7K |
| Feb 2, 2026 | Vairavan Latha | SVP Chief Financial Officer | SELL | 1,320 | $25.50 | $33.7K |
| Feb 2, 2026 | Welgus Howard G. | Director | SELL | 10,000 | $25.05 | $250.5K |
| Feb 2, 2026 | Edwards Larry Todd | See Remarks | SELL | 2,052 | $25.50 | $52.3K |
| Aug 18, 2022 | Burnett Patrick | See Remarks | AWARD | 16,750 | — | — |
8 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 1 mixed, 6 neutral. Avg impact: 3.3/10.
NEUTRAL
8-K
2/10
Arcutis Biotherapeutics filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholder
Jun 9, 2026
NEUTRAL
CLUSTER
3/10
Four Arcutis insiders sold a total of $283K in open-market sales over a one-week window, including t
May 13, 2026
NEUTRAL
144
1/10
Director Patrick Burnett filed a Form 144 notice of intent to sell 222 shares of Arcutis Biotherapeu
May 11, 2026
NEUTRAL
CLUSTER
2/10
Two insiders sold a total of $239K in ARQT shares, representing only 0.008% of market cap. This is t
May 6, 2026
MIXED
PRESS-RELEASE
5/10
Arcutis Biotherapeutics reported Q1 2026 net product revenue of $105.4M (+65% YoY), beating consensu
May 6, 2026
NEUTRAL
PRESS-RELEASE
3/10
Arcutis Biotherapeutics (ARQT) announced it will report Q1 2026 financial results on May 6, 2026, af
Apr 15, 2026
BEARISH
CLUSTER
6/10
Multiple insiders at Arcutis Biotherapeutics sold shares in a coordinated open-market cluster totali
Mar 4, 2026
NEUTRAL
CLUSTER
4/10
Multiple executives at Arcutis Biotherapeutics sold shares in a coordinated open-market transaction
Mar 4, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (86% buy). Based on 14 analysts: 4 strong buy, 8 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$34.63 mean target
+42.0% upside
Strong Buy (1.50)
$33.00 Low
$36.00 High
| Metric | Value |
|---|---|
| Current Price | $24.38 |
| Target Low | $33.00 |
| Target Mean | $34.63 |
| Target Median | $35.00 |
| Target High | $36.00 |
| # Analysts | 8 |
| Recommendation | Strong Buy (1.50) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.05 | $0.02 | $0.08 | 135.9% | -28.2% | 1↑ 1↓ | $0.1B | 43.9% | 3 |
| Next Q 2026-09-30 |
$0.09 | $0.06 | $0.16 | 53.3% | -35.8% | 1↑ 2↓ | $0.1B | 29.9% | 5 |
| Current FY 2026-12-31 |
$0.24 | $0.18 | $0.33 | 288.5% | -33.3% | 1↑ 2↓ | $0.5B | 32.2% | 4 |
| Next FY 2027-12-31 |
$1.16 | $0.79 | $1.61 | 371.7% | -9.6% | 0↑ 3↓ | $0.6B | 29.9% | 7 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.047 | |
| 7d ago | $0.048 | -0.001 |
| 30d ago | $0.065 | -0.018 |
| 60d ago | $0.065 | -0.018 |
| 90d ago | $0.105 | -0.058 |
5 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 7, 2026 | Needham | REITERATE | Buy | Buy |
| Mar 2, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| Feb 27, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Feb 26, 2026 | TD Cowen | MAINTAIN | Buy | Buy |
| Feb 26, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 26, 2026 | Needham | MAINTAIN | Buy | Buy |
| Jan 26, 2026 | Needham | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 8 | 2 | 0 | 0 | 86% | |
| May 1, 2026 | 4 | 8 | 2 | 0 | 0 | 86% | |
| Apr 1, 2026 | 4 | 8 | 2 | 0 | 0 | 86% | |
| Mar 1, 2026 | 4 | 8 | 2 | 0 | 0 | 86% | |
| Feb 1, 2026 | 4 | 8 | 2 | 0 | 0 | 86% | |
| Jan 1, 2026 | 4 | 8 | 2 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
1 members of Congress traded this stock: 1 buys, 0 sells.
Congressional Trades
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Mar 3, 2026 | Gilbert Cisneros | D | HOUSE | BUY | $1,001 - $15,000 | ARCUTIS BIOTHERAPEUTICS INC | Apr 8, 2026 (37d) |
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 29, 2026
fda_pdufa
PDUFA: ARQT — ZORYVE in plaque psoriasis down to 2 years of age — 2026-06-29
FDA target action date 2026-06-29 for ARQT (Arcutis Biotherapeutics, Inc.). Drug: ZORYVE. Indication: plaque psoriasis down to 2 years of age. sNDA fo
Jun 5, 2026
other
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>WESTLAKE VILLAGE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=2S7dOrpOijaVAkfcpjRdFCQbupFyLbC-T
Jun 2, 2026
short_volume
Short Volume: ARQT — 69.7% short (0.8M / 1.1M)
Short: 790,545 | Exempt: 44,232 | TRF Vol: 1,134,042 | Short Ratio: 69.7% | Off-exchange volume (dark pool + OTC)
May 26, 2026
other
Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference
Arcutis today announced that management will present at the Goldman Sachs 47th Annual Global Healthcare Conference, taking place June 8-10, 2026, in M
May 14, 2026
short_volume
Short Volume: ARQT — 55.3% short (0.3M / 0.6M)
Short: 306,537 | Exempt: 2,981 | TRF Vol: 554,173 | Short Ratio: 55.3% | Off-exchange volume (dark pool + OTC)
May 8, 2026
other
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>WESTLAKE VILLAGE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=E2vjsV3r-ZM7tldZH6zD_4qaTUP7AoONIu
May 8, 2026
short_volume
Short Volume: ARQT — 56.9% short (0.6M / 1.0M)
Short: 570,534 | Exempt: 16,506 | TRF Vol: 1,002,480 | Short Ratio: 56.9% | Off-exchange volume (dark pool + OTC)
May 6, 2026
earnings
Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update
Arcutis today reported financial results for the quarter ended March 31, 2026, and provided a business update.
May 6, 2026
earnings_calendar
ARQT Q1 2026 Earnings Scheduled — 2026-05-06
Apr 30, 2026
short_volume
Short Volume: ARQT — 58.2% short (0.3M / 0.6M)
Short: 324,839 | Exempt: 0 | TRF Vol: 558,578 | Short Ratio: 58.2% | Off-exchange volume (dark pool + OTC)
Apr 15, 2026
earnings
Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026
Arcutis today announced that it will report its Q1 2026 financial results and provide a business update on May 6, 2026 after the U.S. markets close.
Mar 31, 2026
other
Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference
Arcutis today announced that Arcutis management will present at the 25th Annual Needham Virtual Healthcare Conference, taking place April 13-16, 2026.
Mar 28, 2026
fda
Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting
Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at 2026 AAD
Feb 25, 2026
earnings_calendar
ARQT Q4 2025 Earnings After Market Close — 2026-02-25
Feb 24, 2026
Clinical Trial
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)
Phase Phase 3 — TERMINATED